中华血液学杂志
中華血液學雜誌
중화혈액학잡지
Chinese Journal of Hematology
2011年
10期
656-659
,共4页
周可树%于珍%易树华%李增军%李玉富%安刚%邹德慧%齐军元%赵耀中%邱录贵
週可樹%于珍%易樹華%李增軍%李玉富%安剛%鄒德慧%齊軍元%趙耀中%邱錄貴
주가수%우진%역수화%리증군%리옥부%안강%추덕혜%제군원%조요중%구록귀
微脱氧核糖核酸%淋巴组织增殖性疾病
微脫氧覈糖覈痠%淋巴組織增殖性疾病
미탈양핵당핵산%림파조직증식성질병
MicroRNA%Lymphoproliferative disorders
目的 观察microRNA-155及microRNA-146a在慢性淋巴细胞白血病(CLL)、套区细胞淋巴瘤(MCL)及脾脏边缘区淋巴瘤(SMZL)患者CD19+B淋巴细胞中的表达,并分析其临床意义.方法 以53例CLL、13例MCL、9例SMZL患者和12名正常人为研究对象.取外周血(78份)或骨髓(9份).常规分离单个核细胞,并行CD19磁珠分选.提取CD19+细胞总RNA,应用TaqMan探针法检测microRNA-155及microRNA-146a的表达,结合患者临床资料进行统计学分析.结果 ①micro RNA-155在CLL患者中的表达(4.49±0.83)显著高于MCL(3.83 ±0.45)及SMZL(3.80±0.61)(P＜0.05)；②SMZL患者中microRNA-146a的表达(3.81±0.59)显著高于CLL(2.58±0.90)及MCL(2.21±0.88)(P＜0.01)；③CLL IgVH未突变组患者microRNA-155的表达显著高于突变组患者(P=0.012);④CLL患者不同细胞遗传学分组间microRNA-155及microRNA-146a的表达差异无统计学意义(P＞0.05).结论 ①不同慢性淋巴增殖性疾病(LPD)之间microRNA-155及microRNA-146a的表达存在差异；②提示microRNA可能与慢性LPD的发病甚至预后相关.
目的 觀察microRNA-155及microRNA-146a在慢性淋巴細胞白血病(CLL)、套區細胞淋巴瘤(MCL)及脾髒邊緣區淋巴瘤(SMZL)患者CD19+B淋巴細胞中的錶達,併分析其臨床意義.方法 以53例CLL、13例MCL、9例SMZL患者和12名正常人為研究對象.取外週血(78份)或骨髓(9份).常規分離單箇覈細胞,併行CD19磁珠分選.提取CD19+細胞總RNA,應用TaqMan探針法檢測microRNA-155及microRNA-146a的錶達,結閤患者臨床資料進行統計學分析.結果 ①micro RNA-155在CLL患者中的錶達(4.49±0.83)顯著高于MCL(3.83 ±0.45)及SMZL(3.80±0.61)(P＜0.05)；②SMZL患者中microRNA-146a的錶達(3.81±0.59)顯著高于CLL(2.58±0.90)及MCL(2.21±0.88)(P＜0.01)；③CLL IgVH未突變組患者microRNA-155的錶達顯著高于突變組患者(P=0.012);④CLL患者不同細胞遺傳學分組間microRNA-155及microRNA-146a的錶達差異無統計學意義(P＞0.05).結論 ①不同慢性淋巴增殖性疾病(LPD)之間microRNA-155及microRNA-146a的錶達存在差異；②提示microRNA可能與慢性LPD的髮病甚至預後相關.
목적 관찰microRNA-155급microRNA-146a재만성림파세포백혈병(CLL)、투구세포림파류(MCL)급비장변연구림파류(SMZL)환자CD19+B림파세포중적표체,병분석기림상의의.방법 이53례CLL、13례MCL、9례SMZL환자화12명정상인위연구대상.취외주혈(78빈)혹골수(9빈).상규분리단개핵세포,병행CD19자주분선.제취CD19+세포총RNA,응용TaqMan탐침법검측microRNA-155급microRNA-146a적표체,결합환자림상자료진행통계학분석.결과 ①micro RNA-155재CLL환자중적표체(4.49±0.83)현저고우MCL(3.83 ±0.45)급SMZL(3.80±0.61)(P＜0.05)；②SMZL환자중microRNA-146a적표체(3.81±0.59)현저고우CLL(2.58±0.90)급MCL(2.21±0.88)(P＜0.01)；③CLL IgVH미돌변조환자microRNA-155적표체현저고우돌변조환자(P=0.012);④CLL환자불동세포유전학분조간microRNA-155급microRNA-146a적표체차이무통계학의의(P＞0.05).결론 ①불동만성림파증식성질병(LPD)지간microRNA-155급microRNA-146a적표체존재차이；②제시microRNA가능여만성LPD적발병심지예후상관.
Objective To investigate the expression of microRNA-155 and microRNA-146a in the CD19+ B cells of chronic lymphocytic leukemia(CLL),mantle cell lymphoma(MCL),splenic marginal zone lymphoma(SMZL),and to analyze its clinical significance.Methods Peripheral blood(PB)(78 cases)and bone marrow(BM)samples(9 cases)from 53 CLL patients,13 MCL patients,19 SMZL patients,and 12 healthy donors were collected.Mononuclear cells were isolated and B cells were purified with a CD19 +magnetic-bead system.Total RNA was extracted from purified CD19 + cells and microRNAs expression were measured using the TaqMan microRNA quantitative PCR.The results combined with the clinic data of patients were analysed.Results ①The expression of microRNA-155 in CLL(4.49 ± 0.83)was significantly higher than in MCL(3.83 ± 0.45)and SMZL(3.80 ± 0.61)(P ＜ 0.05); ②②The level of microRNA-146a in SMZL (3.81 ±0.59)was significantly higher than in CLL(2.58 ±0.90)and MCL(2.27 ±0.88)(P＜0.01);③The level of microRNA-155 was significantly higher in IgVH unmutated patients than in mutated patients in CLL(P =0.012);④The microRNAs expression had no statistical difference between two prognostic groups in CLL.Conclusion ①The expression of microRNA-155 and microRNA-146a is different in malignant lymphoproliferative disorders(LPD);②Deregulation of the microRNAs expression might play a critical role in the pathogenesis and prognosis in the LPD.
